Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Guadecitabine||S110|DNMT inhibitor SGI-110||DNMT inhibitor (Pan) 5||Guadecitabine (SGI-110) is a dinucleotide comprised of decitabine and deoxyguanosine, which inhibits DNA methylation, potentially resulting in decreased tumor cell growth (PMID: 20442312, PMID: 17616700, PMID: 32655143).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||myelodysplastic syndrome||not applicable||Guadecitabine||Phase I||Actionable||In a Phase I trial, SGI-110 treatment resulted in clinical response in 32% (6/19) of patients with myelodysplastic syndrome (PMID: 26296954).||26296954|
|Unknown unknown||acute myeloid leukemia||not applicable||Guadecitabine||Phase I||Actionable||In a Phase I trial, SGI-110 treatment resulted in clinical response in 8% (6/74) of patients with acute myeloid leukemia (PMID: 26296954).||26296954|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02907359||Phase III||Cytarabine Guadecitabine||Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs||Active, not recruiting|
|NCT02131597||Phase II||Guadecitabine||SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS)||Active, not recruiting|
|NCT02096055||Phase II||Cladribine Guadecitabine Idarubicin||4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)||Active, not recruiting|
|NCT02684162||Phase II||Guadecitabine||SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)||Recruiting|
|NCT03165721||Phase II||Guadecitabine||A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer||Completed|
|NCT02348489||Phase III||Guadecitabine Cytarabine Azacitidine Decitabine||SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction||Completed|
|NCT03603964||Phase II||Guadecitabine||Guadecitabine Extension Study||Active, not recruiting|
|NCT02429466||Phase I||Cisplatin Guadecitabine||Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors||Active, not recruiting|
|NCT03075826||Phase II||Guadecitabine||A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms||Active, not recruiting|
|NCT02920008||Phase III||Decitabine Azacitidine Cytarabine Guadecitabine||Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia||Active, not recruiting|
|NCT01966289||Phase I||Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine||SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)||Active, not recruiting|
|NCT03308396||Phase Ib/II||Durvalumab + Guadecitabine Guadecitabine||Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer||Recruiting|